Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Illumina, Guardant Health, PerkinElmer, and More

NEW YORK – Illumina this week celebrated the fifth anniversary of its accelerator program. The sequencing firm accepted five new companies for the Accelerator's tenth funding cycle, including 4Basecare Genomics, a precision oncology company developing personalized diagnostics and treatment guidance for cancer patients in Asia. Over its lifetime, the Illumina Accelerator has graduated 33 companies and helped them raise over $300 million, the company said.

Guardant Health said this week that it has initiated its planned ECLIPSE (Evaluation of ctDNA LUNAR Assay In an Average Patient Screening Encounter) trial, a 10,000-patient observational study that will evaluate the performance of the company's LUNAR-2 circulating cell-free DNA test in detecting colorectal cancer in average-risk adults.

ECLIPSE is now enrolling individuals aged 45 to 84 who are eligible to receive a routine colonoscopy and who meet other criteria like not having certain bowel-related health conditions, not having had a colonoscopy in the past nine years, and not having had another non-invasive CRC test in the last three years. Guardant said the trial will involve multiple sites, but the National Institutes of Health library page for the study currently lists only the Jackson Clinic in Jackson, Tennessee.

The estimated primary completion date for the trial is January 2022, and its final completion date is listed as 2024. If successful, Guardant expects data from ECLIPSE to support a premarket approval submission to the US Food and Drug Administration.

PerkinElmer this week declared a regular quarterly dividend of $.07 per share of its common stock, payable on Feb. 7, 2020 to shareholders of record at the close of business on Jan. 17, 2020.

Affinimark Technologies said this week the US Food and Drug Administration has granted breakthrough designation for the company's cerebrospinal fluid test strip, which is intended for the real-time detection of cerebrospinal fluid leaks. It provides a positive or negative result when suspected fluid is tested, allowing clinicians to make a diagnosis and determination whether intervention is necessary. Affinimark said that the product has gone through the proof of concept and prototyping stages, and the company is initiating a Series C financing round to fund a clinical trial and analytical bench testing over the next 18 months for a de novo510(k) submission to the FDA by Q1 2021.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on GenomeWeb.

Filed under